Microbot Medical stock: Q3 revenue falls as LIBERTY use rises
Published on 11/17/2026 at 22:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly results and rollout
- Third-quarter revenue fell to USD 72,000 from USD 241,000 in the second quarter.
- LIBERTY procedure utilization rose 44%, while customer accounts increased to 12 from 10.
- Microbot expects initial orders under its Israel distribution agreement in the fourth quarter of 2026.
Microbot Medical Inc. filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, on November 16. In a GlobeNewswire release, the company reported revenue of USD 72,000, down from USD 241,000 in the second quarter. Microbot attributed the decline to customer reorder timing, summer seasonality and hospital purchasing reviews.
Revenue pressure meets operating progress
Microbot reported a negative gross margin for the quarter. Cost of goods sold rose 24% from the second quarter, largely because of an inventory write-down and the sale of units manufactured at higher earlier-period costs.
Manufacturing cost per unit continued to decline as production efficiency improved. The company said ongoing cost reductions and a planned second manufacturing line could support positive gross margin during 2027 if completed as planned.
LIBERTY adoption expands
Procedure utilization for the LIBERTY Endovascular Robotic System rose 44% from the second quarter. Customer accounts increased to 12 from 10, while all current customers that had exhausted their initial inventory reordered multiple systems.
Microbot added an academic center in North Carolina and secured its first West Coast customer in California, which is also its first office-based laboratory customer. The company expanded to ten sales territories and plans to reach 12 by the end of 2026.
International expansion and liquidity
Following approval from Israel's Ministry of Health, Microbot entered a three-year exclusive distribution agreement with Medtechnica Ltd. The company expects initial orders under the agreement during the fourth quarter of 2026. It held approximately USD 62 million in cash, cash equivalents and marketable securities at quarter-end.
Microbot Medical stock traded at 0.63 euros on Lang & Schwarz at 22:32 CET on Tuesday, November 17, 2026.
Microbot Medical Inc.
- ISIN: US59503A2042
- WKN: A2N5AS
- Ticker: MBOT
- Primary exchange: Nasdaq
- Lang & Schwarz price: 0.63 euros on November 17, 2026 at 22:32 CET
- Business: Endovascular robotic systems
US equity markets provide the broader setting, with the S&P 500 as the relevant market backdrop.
